Corporate
-
Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated Multiple Myeloma
Janssen, with support from the Multiple Myeloma Research Foundation, opens EAP to help patients in immediate need of new treatment options -
Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates
Pre-Clinical Data Published in Science Forms Basis for Early Human Clinical Trials -
STELARA® Receives European Commission Approval For Treatment Of Adolescents With Moderate-To-Severe Psoriasis In Europe
Approval provides new therapeutic option for plaque psoriasis patients aged 12 and older for whom limited approved treatment options are available -
SIMPONI® Receives European Commission Approval For Treatment Of Non-Radiographic Axial Spondyloarthritis
Approval Marks Fifth Indication for SIMPONI in Europe -
-
Depuy Synthes Companies Announces Five-Year Cooperation Agreement With The AO Foundation
Agreement Continues 55-Year History of Clinical Innovation and Professional Education -
Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
Marks a critical step forward for the investigational human monoclonal antibody (mAb) -
Data at EULAR 2015 Showcase Commitment of Janssen to Advancing Innovative Treatments for Immune and Inflammatory Diseases
New data highlights efficacy and safety of STELARA® (ustekinumab), SIMPONI® (golimumab), sirukumab and guselkumab -
Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients
Results from the Phase 2 MMY2002 trial (Abstract LBA8512) featured in the official press program of the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)